Search

Your search keyword '"Mourah, Samia"' showing total 641 results

Search Constraints

Start Over You searched for: Author "Mourah, Samia" Remove constraint Author: "Mourah, Samia"
641 results on '"Mourah, Samia"'

Search Results

101. Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism

102. Fgf2 induces resistance to nilotinib through mapk pathway activation in kit mutated melanoma

109. Increased risk of brain metastases among patients with melanoma and PROM2 expression in metastatic lymph nodes

116. Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy

117. Eruptive squamous cell carcinomas following an acute skin inflammatory disease: A series of four cases.

119. Highly Sensitive Multivariable Assay Detection of Melanocytic Differentiation Antigens and Angiogenesis Biomarkers in Sentinel Lymph Nodes With Melanoma Micrometastases

125. Cutaneous manifestations of lymphoid‐variant hypereosinophilic syndrome.

126. Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.

127. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec®) in vitro and in vivo

129. Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec ®) in vitro and in vivo

131. EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression

132. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement

135. Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care

137. Discoidin domain receptors: A promising target in melanoma

138. Abstract 3895: A phase I-II pharmacokinetic drug-drug interaction evaluation of oral palbociclib in combination with vemurafenib in patients suffering metastatic melanoma with BRAF V600 mutated and CDKN2A loss & expression of Rb

139. Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.

140. A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors

141. Distinct expression patterns of the E3 ligase SIAH-1 and its partner Kid/KIF22 in normal tissues and in the breast tumoral processes

143. Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial

145. Tre-O2-05 - Macrophage-derived CXCL9 and CXCL11 recruit CD8 T cells in skin and provide long-term disease control in mogamulizumab-treated CTCL patients

147. Bio-O1-01 - Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma

150. Genetic landscape of pulmonary langerhans cell histiocytosis

Catalog

Books, media, physical & digital resources